3,4-二氯苄氧胺盐酸盐 | 15256-10-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二氯苄氧胺盐酸盐
• 中文别名: O-(3,4-二氯苄基)羟胺盐酸盐
• 英文名称: 3,4-dichlorobenzyloxyamine hydrochloride
• 英文别名: O-(3,4-dichlorobenzyl)hydroxylamine hydrochloride；4-((ammoniooxy)methyl)-1,2-dichlorobenzene chloride；(3,4-dichlorophenyl)methoxyamine hydrochloride；O-[(3,4-dichlorophenyl)methyl]hydroxylamine;hydrochloride
• CAS: 15256-10-7
• 化学式: C₇H₇Cl₂NO*ClH
• 分子量: 228.506
• InChiKey: LEUZSWJUEHCRFM-UHFFFAOYSA-N

物化性质

• 熔点：
  195°
• 沸点：
  195°C
• 溶解度：
  DMSO（微溶）、甲醇（微溶）、水（微溶、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2922199090
• 危险类别：
  IRRITANT
• 包装等级：
  III
• 危险性防范说明：
  P240,P210,P241,P264,P280,P302+P352,P370+P378,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险品运输编号：
  1325
• 危险性描述：
  H315,H319,H228

反应信息

• 作为反应物：
  描述：

  3-咪唑-1-基-2,3-二氢色烯-4-酮 、 3,4-二氯苄氧胺盐酸盐 以 甲醇 为溶剂， 生成 N-[(3,4-dichlorophenyl)methoxy]-3-imidazol-1-yl-chroman-4-imine
  参考文献：
  名称：

  Stereoselective Synthesis and in Vitro Antifungal Evaluation of (E)- and (Z)-Imidazolylchromanone Oxime Ethers

  摘要：

  A series of (E)- and (Z)-2,3-dihydro-3-(1 H-imidazol-1 -yl)-4H-1 -benzopyran-4-one oxime ethers have been synthesized and tested for antifungal activity Most compounds showed moderate to potent in vitro antifungal activity. Among the tested compounds, compound (E)-3 d was the most active agent against Candida albicans and Aspergillus niger, and compounds (Z)-(3 a) and (E)-3 a were the most potent compounds against Microsporum gypseum. Detailed stereoselective synthesis, spectroscopic, and biological data are reported.

  DOI：

  10.1002/1521-4184(200209)335:7<318::aid-ardp318>3.0.co;2-o
• 作为产物：
  描述：

  3,4-二氯氯苄 在 盐酸 、 sodium hydroxide 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 39.0h， 生成 3,4-二氯苄氧胺盐酸盐
  参考文献：
  名称：

  Phenoxypropoxybiguanides, Prodrugs of DHFR−Inhibiting Diaminotriazine Antimalarials

  摘要：

  A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine WR99210 (8s), have been prepared. Several of them, such as 5b (PS-33) and 5m. (PS-26), maintain or exceed the in vivo activity of PS-15 while not requiring the use of highly regulated starting materials. The putative diaminotriazine metabolites of these new analogues (compounds 8) have also been prepared and shown to maintain the activity against resistant P. falciparum strains. The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.

  DOI：

  10.1021/jm010089z

文献信息

• Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
  申请人：Meyer Gerhard Adam

  公开号：US20060063841A1

  公开（公告）日：2006-03-23

  Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.

  提供了一种新型三氟甲磺酰苯胺肟醚化合物，可用于控制环境中的内寄生虫和/或外寄生虫，同时提供了制备这些化合物的方法，以及利用这些创新化合物治疗体内或体外寄生虫感染的方法。
• Synthesis and antibacterial evaluation of (E)-1-(1H-indol-3-yl) ethanone O-benzyl oxime derivatives against MRSA and VRSA strains
  作者：Ravikumar Akunuri、Vaishnavi Veerareddy、Grace Kaul、Abdul Akhir、Tanveer Unnissa、Ramulu Parupalli、Y.V. Madhavi、Sidharth Chopra、Srinivas Nanduri

  DOI：10.1016/j.bioorg.2021.105288

  日期：2021.11

  attracted attention of researchers owing to their interesting biological properties. Current work details the synthesis of indole containing oxime ether derivatives and their evaluation for antimicrobial activity against a panel of bacterial and mycobacterial strains. Synthesized compounds demonstrated good to moderate activity against drug-resistant S. aureus including resistant to vancomycin. Among

  由多重耐药菌引起的感染已成为对人类健康的持续威胁。尽管目前有多种抗生素可用于治疗传染病，但仍有大量细菌菌株对其中的许多菌株产生了抗药性。其中，金黄色葡萄球菌引起的感染在成人和儿童人群中占主导地位。吲哚是一种突出的化学支架，存在于许多具有药理活性的天然产品和合成药物中。许多含肟醚的化合物由于其有趣的生物学特性而引起了研究人员的关注。目前的工作详细介绍了含吲哚肟醚衍生物的合成及其对一组细菌和分枝杆菌菌株的抗菌活性的评估。合成的化合物对耐药性金黄色葡萄球菌表现出良好到中等的活性，包括对万古霉素的耐药性。其中，发现化合物5h对金黄色葡萄球菌的敏感菌株以及 MRSA 和 VRSA 菌株具有强效活性具有1μMIC克/毫升和2-4μ克/毫升分别。此外，发现化合物5h对 Vero 细胞无毒，并表现出>40 的良好选择性指数。此外，5h、E -9a和E -9b对金黄色葡萄球菌具有良好的生物膜抑制作用。有了这
• BACTERIOSTATS: III. OXYAMINES AND THEIR DERIVATIVES
  作者：A. F. McKay、D. L. Garmaise、G. Y. Paris、S. Gelblum

  DOI：10.1139/v60-050

  日期：1960.3.1

  A number of benzyloxyamines were prepared for conversion into urea and thiourea derivatives. The benzyloxyamine hydrochlorides on treatment with phosgene gave a mixture of the corresponding benzyl 4-(benzyloxy)-allophanate and benzyloxycarbamyl chloride. Triethylamine converted the benzyloxycarbamyl chlorides into the corresponding 1,3,5-tri-(benzyloxy)-isocyanuric acids. The reactions of the allophanates with amines and sodium hydroxide are described.

  为合成脲和硫脲衍生物，制备了一系列苄氧胺。苄氧胺盐酸盐与光气处理后生成相应的苄基4-(苄氧基)-异尿酸酯和苄氧基氨基甲酰氯的混合物。三乙胺将苄氧基氨基甲酰氯转化为相应的1,3,5-三-(苄氧基)-异氰酸酸。描述了异尿酸酯与胺和氢氧化钠的反应。
• 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES
  申请人：Klar Ulrich

  公开号：US20120316145A1

  公开（公告）日：2012-12-13

  The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, to a process for preparation thereof and to the use thereof as medicaments.

  该发明涉及式I的17-羟基-17-五氟乙基雌二烯-4,9(10)-二烯-11-苄亚甲基衍生物，其中Y和X分别如权利要求和说明书中定义的，以及其制备方法和用作药物的用途。
• Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof
  申请人：Fensholdt Jef

  公开号：US20070244117A1

  公开（公告）日：2007-10-18

  The invention relates to compounds of general formula I wherein D, E, F, G, W, Y, R 1 , A, R 9 , X, B, R 8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer.

  本发明涉及一般式I的化合物，其中D、E、F、G、W、Y、R1、A、R9、X、B、R8如本文所定义，并且其药学上可接受的盐、水合物或溶剂化物，用于治疗与异常血管生成相关的疾病，如癌症，可单独使用或与一个或多个其他药理活性化合物联合使用。